English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduNew drug combinations and targeted therapies may offer a brighter future for patients with acute myeloid leukemia – especially among older adults and others who may be more frail. A review in JAMA Oncology.
Tag: AML
MD Anderson Research Highlights for June 5, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
MD Anderson Research Highlights for May 21, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Multiplication on, multiplication off: Targeting an enzymatic switch to develop oncology drugs
Interdisciplinary research highlighted lipid-protein interaction as a new avenue for oncology drug development, demonstrating its functionality by designing small molecule-based inhibitors to target acute myeloid leukemia.
MD Anderson Research Highlights for January 11, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.
Novel drug combinations and targeted therapies show promise for patients with leukemia
Researchers from The University of Texas MD Anderson Cancer Center are presenting compelling findings from three clinical trials at the 2022 American Society of Hematology (ASH) Annual Meeting. These oral presentations highlight encouraging results to advance the use of targeted therapies and novel combinations in multiple types of leukemia, including high-risk and newly diagnosed acute myeloid leukemia (AML) in older and younger patients and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).
MD Anderson Research Highlights for July 27, 2022
Clinical advances include treating hematologic cancers with effective targeted therapies, circulating tumor DNA as a biomarker for recurrence with colorectal liver metastases, and using magnetic resonance imaging (MRI) to guide surgical decisions for patients with lateral pelvic lymph node metastases in rectal cancer. Laboratory findings offer new understanding of the pancreatic cancer immune microenvironment, melanoma cell states, TP53 mutation status in acute myeloid leukemia (AML), and potential targets for metastatic prostate cancer and GNAS-mutant colorectal cancer.
Memorial Sloan Kettering Cancer Center Receives Highly Competitive NCI SPORE Grant for Leukemia Research with a Focus on Acute Myeloid Leukemia
The National Cancer Institute (NCI) recently awarded Memorial Sloan Kettering Cancer Center (MSK) with a prestigious Specialized Programs of Research Excellence (SPORE) grant for leukemia research. The Translational Research Program (TRP) is the home of the SPOREs — a cornerstone of NCI’s efforts to promote collaborative, interdisciplinary translational cancer research.
Researchers take early step toward leukemia drug therapy
The research team has discovered that for acute myeloid leukemia (AML) patients, there is a dopamine receptor pathway that becomes abnormally activated in the cancer stem cells. This inspired the clinical investigation of a dopamine receptor-inhibiting drug thioridazine as a new therapy for patients, and their focus on adult AML has revealed encouraging results.
New drug combination shows promise as powerful treatment for AML
Scientists have identified two drugs that are potent against acute myeloid leukemia (AML) when combined, but only weakly effective when used alone. The researchers were able to significantly enhance cancer cell death by jointly administering the drugs that are only partially effective when used as single-agent therapies.
Roswell Park Leukemia Chief Shares Promising Findings on New Treatment Options at ASH 2020
Today, during the ASH Annual Meeting and Exposition, Eunice Wang, MD, Chief of Leukemia and Director of Infusion Services at Roswell Park Comprehensive Cancer Center, is presenting data on two ongoing studies incorporating new treatment options for AML.
NCCN Foundation Awards Leading Young Investigators Advancing Cancer Research for Adults and Children
NCCN and the NCCN Foundation announce five new recipients for the 10th annual NCCN Foundation Young Investigator Awards (YIA) Program, overseen by the NCCN Oncology Research Program (ORP)
Cardioprotective Drug Prevents Severe Cardiac Events in Children Undergoing Chemotherapy for Acute Myeloid Leukemia
The cardioprotective drug dexrazoxane preserved cardiac function in pediatric patients undergoing chemotherapy for acute myeloid leukemia (AML) without compromising overall patient survival and potentially improving it, according to a new study by researchers at Children’s Hospital of Philadelphia (CHOP). The results suggest dexrazoxane should be considered for cardioprotection in all pediatric patients undergoing standard chemotherapy for AML.
Small Mutations Identified through Deep DNA Sequencing for AML and MDS
Deep DNA sequencing analysis conducted by Rutgers Cancer Institute of New Jersey investigators examining genomic differences within tumors for prediction of disease relapse in certain hematologic malignancies has identified small mutations. These may help further guide treatment decision making for patients.
Combination therapy more effective than chemotherapy alone for many newly diagnosed leukemia patients
A Phase II study pairing azacitidine with enasidenib boosts complete remission in patients with AML with IDH2 mutations.